Recent Updates
Recently added Catalysts
HCM Positive Sentiment

Appointment of Cavendish as Joint Corporate Broker in London Hong Kong, Shanghai & Florham Park, NJ - Tuesday

Tuesday, December 31, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: HUTCHMED (China) Limited has announced the appointment of Cavendish Capital Markets Limited as its new joint Corporate Broker in London, effective January 1, 2025. This strategic addition complements the existing roles of Panmure Liberum Limited and HSBC Bank plc, who will continue their involvement as joint brokers. The move aims to strengthen HUTCHMED's presence in the London market and comply with AIM rules through its nominated advisor.
Price reaction · baseline $14.36 (2024-12-30 close) · hit after-hours · 1 other HCM headline(s) in the window, move may be shared
day 0 close
+0.3%

Market Sentiment Analysis

POSITIVE FACTORS

  • Appointment of Cavendish Capital Markets as joint Corporate Broker indicates growth and strategic partnership.
  • Continued collaboration with established firms like Panmure Liberum and HSBC enhances credibility.
  • Broadened support in London may improve market presence for HUTCHMED.

Full Press Release Details

Appointment of Cavendish as Joint Corporate Broker in London
Hong Kong, Shanghai & Florham Park, NJ - Tuesday, December 31, 2024: HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13) today announces that it has appointed Cavendish Capital Markets Limited as its joint Corporate Broker in London with effect from January 1, 2025. Panmure Liberum Limited and HSBC Bank plc will continue to act as joint Corporate Brokers in London and Panmure Liberum Limited will continue to act Nominated Advisor to HUTCHMED in London in respect of the AIM rules.
Investor Enquiries +852 2121 8200 / ir@hutch-med.com
Media Enquiries
Ben Atwell / Alex Shaw, FTI Consulting +44 20 3727 1030 / +44 7771 913 902 (Mobile) / +44 7779 545 055 (Mobile) / HUTCHMED@fticonsulting.com
Zhou Yi, Brunswick +852 9783 6894 (Mobile) / HUTCHMED@brunswickgroup.com
Nominated Advisor
Atholl Tweedie / Freddy Crossley / Rupert Dearden, Panmure Liberum +44 (20) 7886 2500

Frequently Asked Questions

Who has been appointed as HUTCHMED's joint Corporate Broker?

Cavendish Capital Markets Limited has been appointed as HUTCHMED's joint Corporate Broker.

When will Cavendish start its role as Corporate Broker?

Cavendish will begin its role as joint Corporate Broker on January 1, 2025.

Which firms are continuing to act as Corporate Brokers for HUTCHMED?

Panmure Liberum Limited and HSBC Bank plc will continue as joint Corporate Brokers.

Who is the Nominated Advisor for HUTCHMED?

Panmure Liberum Limited will serve as the Nominated Advisor in London.

How can investors contact HUTCHMED for inquiries?

Investors can reach HUTCHMED at +852 2121 8200 or ir@hutch-med.com.

ShareAdd on Google
Tags: HCM Viatris Investor Conferences Healthcare HUTCHMED Cavendish Corporate Broker Hong Kong London
Last updated: Dec 31, 2024

Biotech snapshot

Lead asset
SavolitinibPhase 3
Non-small Cell Lung Cancer Metastatic →